Tavlesse is a medicine for treating adults with chronic immune thrombocytopenia. It is for use when other treatments have not worked. Chronic immune thrombocytopenia, previously called idiopathic thrombocytopenic purpura (ITP), is a long-term condition in which the immune system (the body’s defences) destroys healthy platelets in the blood. Platelets are needed to form clots and stop bleeding. Patients with the disease have low platelet counts and may bruise or bleed easily. Tavlesse contains the active substance fostamatinib.
Therapeutic Indication
### Therapeutic indication Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
Therapeutic Area (MeSH)
ATC Code
B02BX
ATC Item
其它系统止血药
Pharmacotherapeutic Group
Other systemic hemostatics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Fostamatinib disodium | N/A | 福他替尼 |
EMA Name
Tavlesse
Medicine Name
Tavlesse
Aliases
N/ANo risk management plan link.
